SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BMcV who wrote (2863)5/19/1999 10:43:00 PM
From: Bob Swift  Read Replies (2) of 10280
 
With respect to partnering with a big pharm, it is interesting that Claritin was compared with Nori in the clinical trial. Despite being out to dinner,I still think one cannot rule out the possibility of a SGP licensing. SGP could licenses Nori but not seriously promoting it. That way Nori does not fall into the wrong hand(e.g.Glaxo) and SGP wipes out possible competition for DCL. Moreover, if Claritin 2 turns out to be no better than Claritin 1 and they faces generic competition, they can always promote the proven superior Nori instead and thereby maintain their share of the market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News